Gabriella Bröms

Gabriella Bröms

Auto-generated profile, based on publicly available information

Gabriella Bröms

Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2014 in Inflammatory Bowel Diseases
Verified
Journal Article
Open access
PDF file
GBGabriella Bröms
Gabriella Bröms
FGFredrik Granath
Fredrik Granath
MLMarie Linder
Marie Linder
OSOlof Stephansson
Olof Stephansson
MEMaria Elmberg
Maria Elmberg
HKHelle Kieler
Helle Kieler
Background. Ulcerative colitis (UC) and Crohn's disease (CD) have been associated with increased risks of adverse birth outcomes. Disease activity and drug expo

1 February 2016 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
GBGabriella Bröms
Gabriella Bröms
FGFredrik Granath
Fredrik Granath
AEAnders Ekbom
Anders Ekbom
KHKarin Hellgren
Karin Hellgren
LPLars Pedersen
Lars Pedersen
HKHelle Kieler
Helle Kieler

1 November 2012 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
GBGabriella Bröms
Gabriella Bröms
FGFredrik Granath
Fredrik Granath
MLMarie Linder
Marie Linder
OSOlof Stephansson
Olof Stephansson
MEMaria Elmberg
Maria Elmberg
HKHelle Kieler
Helle Kieler

4 February 2020 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
GBGabriella Bröms
Gabriella Bröms
HKHelle Kieler
Helle Kieler
AEAnders Ekbom
Anders Ekbom
MGMika Gissler
Mika Gissler
KHKarin Hellgren
Karin Hellgren
FGFredrik Granath
Fredrik Granath

12 April 2020 in Schizophrenia Research
Verified
Journal Article
Open access
JRJohan Reutfors
Johan Reutfors
CCCarolyn Cesta
Carolyn Cesta
JCJacqueline M. Cohen
Jacqueline M. Cohen
BBBrian T. Bateman
Brian T. Bateman
RBRuth Brauer
Ruth Brauer
GBGabriella Bröms
Gabriella Bröms
To compare the prevalence and trends of antipsychotic drug use during pregnancy between countries across four continents. Individually linked health data in Denmark (2000-2012), Finland (2005-2014), Iceland (2004-2017), Norway (2005-2015), Sweden (2006-2015), Germany (2006-2015), Australia (New South Wales, 2004-2012), Hong Kong (2001-2015), UK (2006-2016), and the US (Medicaid, 2000-2013, and IBM MarketScan, 2012-2015) were used. Using a uniformed approach, we estimated the prevalence of antipsychotic use as the proportion of pregnancies where a woman filled at least one antipsychotic prescription within three months before pregnancy until birth. For the Nordic countries, data were meta-analyzed to investigate maternal characteristics associated with the use of antipsychotics. We included 8,394,343 pregnancies. Typical antipsychotic use was highest in the UK (4.4%) whereas atypical antipsychotic use was highest in the US Medicaid (1.5%). Atypical antipsychotic use increased over time in most populations, reaching 2% in Australia (2012) and US Medicaid (2013). In most countries, prochlorperazine was the most commonly used typical antipsychotic and quetiapine the most commonly used atypical antipsychotic. Use of antipsychotics decreased across the trimesters of pregnancy in all populations except Finland. Antipsychotic use was elevated among smokers and those with parity ≥4 in the Nordic countries. Antipsychotic use during pregnancy varied considerably between populations, partly explained by varying use of the typical antipsychotic prochlorperazine, which is often used for nausea and vomiting in early pregnancy. Increasing usage of atypical antipsychotics among pregnant women reflects the pattern that was previously reported for the general population.

24 July 2020 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
GBGabriella Bröms
Gabriella Bröms
HKHelle Kieler
Helle Kieler
AEAnders Ekbom
Anders Ekbom
MGMika Gissler
Mika Gissler
KHKarin Hellgren
Karin Hellgren
FGFredrik Granath
Fredrik Granath
Summary: Background: Most anti‐tumour necrosis factor (anti‐TNF) agents are transferred across the placenta and may increase paediatric susceptibility to infections.Aims: To assess the risk of paediatric infections after maternal anti‐TNF treatment.Methods: Population‐based cohort study in Denmark, Finland and Sweden 2006‐2013 in which 1027 children born to women with rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis or inflammatory bowel disease, treated with anti‐TNF, and 9346 children to women with non‐biologic systemic treatment, were compared to 1 617 886 children of the general population. Children were followed for 3 years.Results: Adjusted by maternal age, parity, smoking, body mass index, country and calendar year, the incidence rate ratios with 95% confidence interval (CI) for hospital admissions for infection in the first year were 1.43 (1.23‐1.67) for anti‐TNF and 1.14 (1.07‐1.21) for non‐biologic systemic treatment, and 1.29 (1.11‐1.50) and 1.09 (1.02‐1.15), respectively, when additionally adjusting for adverse birth outcomes. There was a slight increase in antibiotic prescriptions in the second year for anti‐TNF, 1.19 (1.11‐1.29), and for non‐biologic systemic treatment, 1.10 (1.07‐1.13). There was no difference among anti‐TNF agents, treatment in the third trimester, or between mono/combination therapy with non‐biologic systemic treatment.Conclusions: Both anti‐TNF and non‐biologic systemic treatment were associated with an increased risk of paediatric infections. However, reassuringly, the increased risks were present regardless of treatment in the third trimester, or with combination treatment, and were not persistent during the first 3 years of life. Our findings may indicate a true risk, but could also be due to unadjusted confounding by disease severity and healthcare‐seeking behaviour. This may in turn shift the risk‐benefit equation towards continuation of treatment even in the third trimester.